141 related articles for article (PubMed ID: 11144027)
21. Estrogen blocks parathyroid hormone-stimulated osteoclast-like cell formation in modulating differentiation of mouse marrow stromal cells in vitro.
Liu BY; Wu PW; Hsu YT; Leu JS; Wang JT
J Formos Med Assoc; 2002 Jan; 101(1):24-33. PubMed ID: 11911034
[TBL] [Abstract][Full Text] [Related]
22. Osteoblasts from the toothless (osteopetrotic) mutation in the rat are unable to direct bone resorption by normal osteoclasts in response to 1,25-dihydroxyvitamin D.
Sundquist KT; Jackson ME; Hermey DC; Marks SC
Tissue Cell; 1995 Oct; 27(5):569-74. PubMed ID: 7491626
[TBL] [Abstract][Full Text] [Related]
23. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
24. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact.
Jimi E; Nakamura I; Amano H; Taguchi Y; Tsurukai T; Tamura M; Takahashi N; Suda T
Endocrinology; 1996 Aug; 137(8):2187-90. PubMed ID: 8754795
[TBL] [Abstract][Full Text] [Related]
25. Lack of bone resorption in osteosclerotic (oc/oc) mice is due to a defect in osteoclast progenitors rather than the local microenvironment provided by osteoblastic cells.
Udagawa N; Sasaki T; Akatsu T; Takahashi N; Tanaka S; Tamura T; Tanaka H; Suda T
Biochem Biophys Res Commun; 1992 Apr; 184(1):67-72. PubMed ID: 1567458
[TBL] [Abstract][Full Text] [Related]
26. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity.
Martin TJ; Ng KW
J Cell Biochem; 1994 Nov; 56(3):357-66. PubMed ID: 7876329
[TBL] [Abstract][Full Text] [Related]
28. Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells: studies using VDR knockout mice.
Takeda S; Yoshizawa T; Nagai Y; Yamato H; Fukumoto S; Sekine K; Kato S; Matsumoto T; Fujita T
Endocrinology; 1999 Feb; 140(2):1005-8. PubMed ID: 9927335
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.
Murakami T; Yamamoto M; Ono K; Nishikawa M; Nagata N; Motoyoshi K; Akatsu T
Biochem Biophys Res Commun; 1998 Nov; 252(3):747-52. PubMed ID: 9837778
[TBL] [Abstract][Full Text] [Related]
30. 1,25-Dihydroxyvitamin D3 stimulates rat osteoblastic cells to release a soluble factor that increases osteoclastic bone resorption.
McSheehy PM; Chambers TJ
J Clin Invest; 1987 Aug; 80(2):425-9. PubMed ID: 3611354
[TBL] [Abstract][Full Text] [Related]
31. Basic fibroblast growth factor inhibits osteoclast formation induced by 1alpha,25-dihydroxyvitamin D(3) through suppressing the production of osteoclast differentiation factor.
Nakagawa N; Yasuda H; Yano K; Mochizuki Si; Kobayashi N; Fujimoto H; Yamaguchi K; Shima N; Morinaga T; Higashio K
Biochem Biophys Res Commun; 1999 Nov; 265(1):45-50. PubMed ID: 10548488
[TBL] [Abstract][Full Text] [Related]
32. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.
Vitté C; Fleisch H; Guenther HL
Endocrinology; 1996 Jun; 137(6):2324-33. PubMed ID: 8641182
[TBL] [Abstract][Full Text] [Related]
33. The human osteoclast precursor circulates in the monocyte fraction.
Fujikawa Y; Quinn JM; Sabokbar A; McGee JO; Athanasou NA
Endocrinology; 1996 Sep; 137(9):4058-60. PubMed ID: 8756585
[TBL] [Abstract][Full Text] [Related]
34. Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts.
Lundberg P; Lie A; Bjurholm A; Lehenkari PP; Horton MA; Lerner UH; Ransjö M
Bone; 2000 Dec; 27(6):803-10. PubMed ID: 11113391
[TBL] [Abstract][Full Text] [Related]
35. Reduced bone resorption in toothless (osteopetrotic) rats--an abnormality of osteoblasts related to their inability to activate osteoclast activity in vitro.
Hermey DC; Popoff SN; Marks SC
Connect Tissue Res; 1996; 35(1-4):273-8. PubMed ID: 9084666
[TBL] [Abstract][Full Text] [Related]
36. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity.
Kanatani M; Sugimoto T; Kaji H; Kobayashi T; Nishiyama K; Fukase M; Kumegawa M; Chihara K
J Bone Miner Res; 1995 Nov; 10(11):1681-90. PubMed ID: 8592944
[TBL] [Abstract][Full Text] [Related]
37. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function.
Hill PA; Reynolds JJ; Meikle MC
Endocrinology; 1995 Jan; 136(1):124-31. PubMed ID: 7828521
[TBL] [Abstract][Full Text] [Related]
38. Effects of 22-oxacalcitriol on bone metabolism in vitro: comparison with calcitriol--effects of 22-oxacalcitriol on osteoclast-like cell formation and bone-resorbing activity.
Kanatani M; Sugimoto T; Kaji H; Kano J; Chihara K
Eur J Endocrinol; 1995 Nov; 133(5):618-25. PubMed ID: 7581994
[TBL] [Abstract][Full Text] [Related]
39. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells.
Jimi E; Nakamura I; Duong LT; Ikebe T; Takahashi N; Rodan GA; Suda T
Exp Cell Res; 1999 Feb; 247(1):84-93. PubMed ID: 10047450
[TBL] [Abstract][Full Text] [Related]
40. Deficiency of osteoclasts in osteopetrotic mice is due to a defect in the local microenvironment provided by osteoblastic cells.
Takahashi N; Udagawa N; Akatsu T; Tanaka H; Isogai Y; Suda T
Endocrinology; 1991 Apr; 128(4):1792-6. PubMed ID: 2004603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
